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Pain affects approximately 80% of patients with pancreatic cancer, with half requiring strong 
opioid analgesia, namely: morphine-based drugs on step three of the WHO analgesic ladder 
(as opposed to the weak opioids: codeine and tramadol). The presence of pain is associated 
with reduced survival. This article reviews the literature regarding pain: prevalence, 
mechanisms, pharmacological and endoscopic treatments, and identifies areas for research to 
develop individualised patient pain management pathways. The online literature review was 
conducted through: PubMed, Clinical Key, Uptodate and NICE Evidence. There are two 
principal mechanisms for pain: pancreatic duct obstruction and pancreatic neuropathy which 
respectively activate mechanical and chemical nociceptors. In pancreatic neuropathy several 
histological, molecular and immunological changes occur which correlate with pain including: 
transient receptor potential cation channel activation and mast cell infiltration. Current pain 
management is empirical rather aetiology-based and is informed by the WHO analgesic ladder 
for first line therapies, and then endoscopic ultrasound guided celiac plexus neurolysis (EUS-
CPN) in patients with resistant pain. For EUS-CPN, there is only one clinical trial reporting a 
benefit, which has limited generalisability. Case series report pancreatic duct stenting (PDS) 
gives effective analgesia, but there are no clinical trials. Progress in understanding the 
mechanisms for pain and when this occurs in the natural history, together with assessing new 
therapies both pharmacological and endoscopic, will enable individualised care and may 
improve patients’ quality of life and survival.  
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Pancreatic cancer has the worst prognosis of any tumour and there has been little 
improvement in survival in recent decades despite the availability of new treatments. 
Approximately 266,000 pancreatic cancer related deaths are recorded worldwide every year, 
making it the fourth commonest cause of cancer-related death (3), (4). Most patients have 
surgically inoperable disease and are referred for palliative care. This paper reviews several 
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aspects of pain in patients with pancreatic cancer including: its prevalence, the mechanisms of 
pain, the pharmacological and endoscopic treatment options and future developments in this 
clinical area. The literature review was conducted online from February to June 2016, using: 
PubMed, Clinical Key, Uptodate and NICE Evidence Search. Different search terms were used 
for different sections of the article, namely: ‘prevalence of pain in pancreatic cancer’, 
‘pancreatic neuropathy’, ‘pharmacotherapy in pancreatic cancer pain’, ‘endoscopic ultrasound 
guided coeliac plexus neurolysis’, ‘pancreatic duct stent’ and ‘ chemotherapy for pain relief’. 
Included papers were: systematic reviews, randomised controlled trials, cohort studies, case-
control studies and case reports. The bibliographies were scanned for other relevant 
references not detected at the initial search.  
Prevalence of pain at presentation and its clinical significance 
 
Abdominal pain in patients with pancreatic cancer is a common complication, associated with 
reduced performance status and decreased survival. Pain is the third commonest symptom 
(72%) in patients with cancer in the head of pancreas after weight loss (92%) and jaundice 
(82%) and second (87%) when the tumour is in the body or tail (6). At diagnosis 30-40% of 
patients report abdominal pain, 80% develop pain as the cancer progresses and in 44% of these 
it is described as severe (7). Pain scores are nearly four times higher in patients with impaired 
performance status scores i.e. ECOG (Eastern Co-operative Group) ≥1 or KPS (Karnofsky 
Performance Score) ≤80%, compared to those with normal scores (p< 0.001) (8). Pain at 
diagnosis predicted poor survival in a case series of 136 patients who underwent palliative 
gastric bypass [hazard ratio for death of patients with pain to patients without was 1.61 (95%CI, 
1.06 -2.44) (p= 0.025)] (9). The median survival times during an 18 month follow up period for 
patients with: ‘occasional’, ‘daily’ and ‘daily and strong’ pain were: 9.4, 7.6 and 3.5 months 
respectively (p=0.0017) (9). Another observational study of 149 patients, who underwent 
pancreatic tumour resection were classed pre-operatively into three pain groups based on 
their pain intensity and frequency, and measured survival as the time between surgery and 
cancer-specific death (14). The median survivals for patients with no pain, mild pain and 
moderate to severe pain were 21.5, 15.0 and 10.0 months respectively (P= 0.0015) (14). It is 
unclear why patients with pain have worse survival than those without and whether better 
analgesia would prolong survival. Pain is probably an indicator of other predictors of survival 
such as advanced cancer staging or poor nutritional status and such patients have impaired 
performance status scores, therefore are more likely to be ineligible for chemotherapy. 
Importantly, the natural history of pain, including its time of onset after diagnosis, progression 
and clinical characteristics, are poorly documented in the literature, an understanding of which 
would help guide the timing of therapeutic interventions to promote better analgesia. 
Pain mechanisms in pancreatic cancer 
 
Pancreatic neuroanatomy 
An appreciation of the neuroanatomy of the pancreas is important to understand the 
mechanisms of pain and the potential for therapeutic options. There are complex neuronal 
pathways which transmit pain signals generated in the pancreas itself to the cerebral cortex. 
The gland is innervated by both sympathetic and parasympathetic fibres of the autonomic 
nervous system. Mechanical or chemical noxious stimuli activate nerve endings within the 
gland releasing several neurotransmitters (10) including the endecapeptide Substance P (SP) 
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and the 37 amino-acid peptide Calcitonine Gene Related Peptide (10). Afferent neurons from 
the pancreas connect to the coeliac plexus and the electrical signals are then transmitted 
through the dorsal horns to the dorsal route ganglia at the T2- L2 spinal level. Impulses ascend 
through the spinothalamic, spinoreticular, spinomesencephalic, spinohypothalamic fibres to 
higher centres in the: thalamus, hypothalamous, brainstem and terminate in the primary 
somatosensory cerebral cortex (10). The stimulus for pain in pancreatic cancer is due to both 
neural activation and nerve damage. The longstanding exposure to noxious stimuli, plus the 
release of molecular products from the tumour, promote altered neuroplasticity including 
altered pain perception (allodynia), hyperexcitability of the nervous system, inflammatory cell 
infiltration and activation of mitogenic pathways in afferent neurons which are quiescent in 
normal pancreatic tissue. There are two principal mechanisms which probably lead to pain in 
pancreatic cancer namely: ductal obstruction and pancreatic neuropathy. 
Pancreatic Ductal Obstruction 
Pancreatic duct obstruction by the cancer typically causes epigastric or right upper quadrant 
pain and is provoked by release of pancreatic juices on eating. The mechanism of ductal 
obstructive pain has not been fully investigated, however, it is thought to be similar to that of 
chronic pancreatitis. Occlusion of the duct blocks the flow of digestive enzymes and leads to 
increased interstitial and intraductal pressures (11). These promote parenchymal oedema and 
decreased pancreatic blood flow and, similar to the pain of compartment syndromes, generate 
ischaemic pain. Obstructive flow causes dilatation of the pancreatic duct, which is detectable 
on CT, MR imaging of the pancreas and ERCP. The correlation between obstructive type pain 
and radiological duct dilatation has not been reported in the literature. Biliary stenting for 
jaundice may also relieve pancreatic ductal obstruction and hypothetically promote analgesia. 
Several clinical case series have reported that pancreatic ductal stenting in patients with typical 
obstructive-type pancreatic abdominal pain and radiologically confirmed pancreatic duct 
dilatation led to either a complete resolution or at least improvement of the pain (12), (13) 
(table 1). These clinical studies did not include a comparative group where patients were 
treated with drug analgesia only. Duct stenting involves deep cannulation of the major 
pancreatic duct and insertion of a guidewire across the stricture. Dilatation is then performed, 
using either a catheter or a balloon followed by stent insertion. The most recent such case 
series performed pancreatic stenting in 20 patients with typical obstructive pain and 
documented decreases in: the (VAS) pain score compared to pre-treatment [from 6.7 points 
to 3.1 points at 4 weeks (P < 0.001)], in fentanyl consumption [from 85.5 μg/h, to 57.9 μg/h at 
4 weeks (P < 0.01), to 60.5 μg/h at 8 weeks (P<0.01) and to 64.1 μg/h at 12 weeks (P < 0.01)]. 
Four other case series have reported total pain resolution between 41% to 87% of patients 
(13).  Bleeding and dislodgement of the stent were documented but were not associated with 
mortality (13). In the above case series, none of the 70 patients who underwent pancreatic 
duct stenting developed clinical pancreatitis, cholangitis, ductal rupture, guidewire fracture 
requiring surgical removal or stent migration into the gland. These are complications described 
in patients stented for other pathologies (chronic pancreatitis, pancreas divisium, benign 
pancreatic duct strictures, autoimmune cholangiopathy). The current literature reports, 
namely clinical series, that pancreatic duct stenting is safe and beneficial for inducing pain relief 
and decreasing opioid consumption. Randomised controlled trials are required to investigate 
any efficacy of stenting before it may be considered as part of standard care for inducing 
analgesia. Such trials would be logistically difficult to conduct as patients at this time maybe 
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undergoing other intensive treatments such as chemotherapy and endoscopic relief of 
jaundice. 
Pancreatic neuropathy 
The second mechanism for the generation of pain involves direct damage to the pancreatic 
nerves themselves. Several histopathological and molecular changes have been observed in 
pancreatic cancer specimens which are associated with pain namely: increased nerve density 
and nerve hypertrophy, peri- and endo- neural cancer cell invasion, altered expression of 
nociceptors, parenchymal immune cell infiltration in the pancreas and release of neurotrophic 
growth factors which are undetectable in the normal pancreas. These changes comprise a 
phenomenon referred to either as: pancreatic neuropathy, neuritis or neurogenic 
inflammation. Pancreatic tissue architecture is distorted by cancer cell infiltration, promoting 
activation of local immune cells and further damage due to inflammation (10).  
The first histological observation in pancreatic neuropathy, the number of nerve endings per 
unit area (nerve density) in the pancreas and the total nerve area (nerve hypertrophy) were 
examined in 149 human surgical specimens post-pancreatic cancer resection (14). Prior to 
surgery pain was classified based firstly on its intensity (0=none, 1= mild, 2= moderate, 3= 
strong) and secondly its frequency (3=daily, 2= weekly, 1= monthly) and the multiple of the 
two was the registered pain score. Nerve density and hypertrophy were increased 14 and 2 
times respectively, compared to that in non-cancerous tissue obtained from organ donors 
(p<0.01)  (14). Patients with pancreatic cancer who reported severe pain had a threefold 
greater nerve hypertrophy compared to those with mild pain (P<0.0001) or were pain free 
(P<0.0001). Immune cell infiltration, perineural invasion and neurotrophic cytokines released 
by the tumour and immune cells lead to mitotic phenomena that increased the number and 
size of pancreatic neurons (14).  
The second histopathological observation in pancreatic neuropathy is the invasion of malignant 
cells into the perineurium, the connective tissue that surrounds and supports the neurons 
which is detected in 79% of pancreatic adenocarcinomas (14). In adenocarcinoma, the invasion 
is typically more extensive than in the other neoplasms as it can also involve the endoneurium, 
axons and Schwann cells. In pNETS and IPMNs cancer cell invasion is restricted to the 
perineurium. In the above series (14) the severity of neural invasion was classified as either: i) 
no invasion= 0, ii) perineural invasion=1 or iii) endoneural invasion=3 and the frequency as i) 
absent=0. ii) low= 1, iii) frequent= 2 and iv) excessive= 3. The multiple of those two was the 
mean neural cancer cell invasion score. Patients reporting severe pain had nearly the twice 
mean neural cancer cell invasion score compared to those with no pain (p< 0.05) and mild pain 
(p<0.001) (14) (scores were 3.8, 2 and 1.8 respectively).  
Thirdly, local inflammation activates the expression of TRPV1 (transient receptor potential 
cation channel) in the intrapancreatic nerves endings, a cation channel that conducts sodium 
and calcium influx into the neurons and facilitates the generation of action potentials (15). This 
releases Substance P (SP) and Calcitonin Gene- Related Peptide (CGRP) (10), (15), two 
neurotransmitters which conduct pain signals from the parenchyma to the dorsal root ganglia. 
These also have cytokine-like properties including: chemotaxis, neutrophil extravasation, 
further macrophage activation, mast cell degranulation and release of pro-inflammatory 
molecules namely TNF-a, IL1,-2,-6,-8 (14).  TRPV1 is overexpressed in pancreatic cancer tissue 
and is associated with the development of pain (14). The pain scores of 32 patients [mean age 
64.1 years] prior to Whipple’s surgery were measured and classified into one of three groups 
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(1= no pain, 2= controlled pain with non-steroidal anti- inflammatory drugs, 3= use of opioid 
analgesics). Post-operative real time PCR (polymerase chain reaction) and 
immunohistochemistry quantified and localised TVPR1 in the resected pancreas. There was a 
positive linear association between TVRP1 mRNA levels and the intensity of pain reported (p< 
0.0001). This over-expression of the cation channel facilitates the influx of cations into the 
nociceptive neurons and may be responsible for their increased sensitivity and therefore 
lowers the threshold for generating action potentials promoting hyperalgesia (a weak 
stimulant perceived as strong one), hyperexcitability and allodynia (perception of a non-painful 
stimulant as painful) (16).  
Fourthly, immune cell clusters around the local pancreatic nerves are observed in pancreatic 
cancer tissue (17). These clusters are predominantly mast cells, T-lymphocytes and 
macrophages whilst others, such as eosinophils, B-lymphocytes and plasma cells, are rarely 
present (17). A clinical study investigated the association between reported pain and the 
presence of specific types of immune cells, in 20 tissue specimens from patients [mean age 66 
years] who underwent pancreatectomy. Prior to surgery, pain was documented in participants. 
Patients who reported pain had pancreatic tissue infiltrated predominantly by mast cells, as 
opposed to those without pain where there was infiltration by T-lymphocytes (p <0.05) (17). 
This observation, in addition to the fact that SP, CGRP and NGF bind to mast cells receptors 
and promote their degranulation and release of proteases, tryptases and histamine supports 
a link between the immune and the nerve systems in the generation of pancreatic cancer pain 
(17).  
Finally, another important molecule in the nociceptive pathway is Nerve Growth Factor (NGF). 
This is a neuropeptide, normally undetectable in the healthy pancreas but secreted by 
fibroblasts, immune, pancreatic and Schwann cells in response to neural injury to promote 
repair and regeneration (15). NGF is a pro-inflammatory cytokine, promoting chemotaxis and 
further release of SP and CGRP. This peptide binds to the TrkA receptor (Tropomyocin kinase 
receptor), which promotes cancer cell proliferation in the perineural spaces (25). NGF and TrkA 
mRNA levels were increased 2.7-fold and 5.6-fold, respectively (P <0.05 and P <0.05) in 
pancreatic cancer tissue and were associated with high pain scores (P <0.01) (14). Moreover, 
NGF caused hyperalgesia when exogenously administered in mice (14).  
In summary, there are several histopathological and molecular changes contributing to the 
generation of neuropathic pain in patients with pancreatic cancer, although the relative 
contributions of each to symptoms are unknown. Clarifying this uncertainty is important, as it 
may lead to the development of new pharmacological agents to target these systems such as 
TVRP1 blockers or NGF, SP, CGRP antagonists.  
 
Analgesic drugs for pancreatic cancer pain 
 
The requirement for analgesia should always be assessed in patients with pancreatic cancer by 
clinicians at diagnosis and at all subsequent follow up visits. There are both pharmacological 
and endoscopic options for relieving pain but drugs are invariably prescribed initially.  The main 
therapeutic aim is to prevent pain, rather than control pain when it is already established. The 
choice of appropriate pharmacotherapy is informed by the WHO analgesic ladder (18), starting 
with prescribing mild painkillers, such as paracetamol and non-steroidal anti-inflammatory 
 7 
 
drugs. Clinicians may progress to prescribing weak opioids, such as codeine, dihydrocodeine or 
tramadol (18). If these drugs are ineffective, stronger morphine-based analgesics are indicated. 
If the patient is unable to tolerate oral medications, strong opioid analgesics can be 
administered transdermaly. Alfentanyl is used in patients with renal impairment, as it does not 
accumulate systemically like other opioid analgesics. Formulations containing combinations of 
oxycodone and the opioid antagonist naloxone minimise opioid-related side effects, 
particularly constipation. Other adverse effects include: nausea, sedation, cough suppression, 
dry mouth, and pruritus all of which impair patients’ quality of life (19). When strong opioids 
have failed methadone and ketamine, two NMDA (N-methyl-D –aspartate) receptor 
antagonists are options (19). NMDA acts in the dorsal route ganglia and transmits pain signals 
to the central nervous system. Patients with pancreatic cancer have severe gastrointestinal 
symptoms due to the cancer itself which are similar to the side effects of the opioid analgesics 
themselves and complicate their use. For this reason there are alternative routes of 
administration of analgesics including rectal, transdermal and subcutaneous ones (18). 
Tricyclic antidepressants (TCAs) and gabapentinoids also have a role in controlling neuropathic 
pain. The neuroplasticity of the central nervous system has been studied in malignant and non-
malignant peripheral neuropathies and other painful disorders, such as non-erosive 
oesophageal reflux disease (NERD) and irritable bowel syndrome (IBS). This may be altered 
when peripheral pain persists, leading to hyperexcitability of neurons and lowering of pain 
thresholds to stimuli that would not normally generate nociceptive signals in healthy 
individuals (19). Tricyclic antidepressants (TCAs) and gabapentinoids both have peripheral and 
central pharmacological actions and have been investigated for their analgesic effects in 
patients with several types of cancer. The TCAs, amitriptyline and nortriptyline, antagonise 
centrally-acting neurotransmitters at receptors, namely norepinephrine and NMDA, and can 
be used as adjuvant treatments in the WHO ladder of drugs. However, TCAs have 
anticholinergic side effects namely: dry mouth, constipation, urinary retention, blurred vision 
and orthostatic hypertension which can limit their use (19). Gabapentinoids, i.e. gabapentin 
and pregabalin, block calcium channels in nociceptors and decrease the release of substance 
P, norepinephrine and glutamate. They are effective treatments for allodynia, although their 
therapeutic action requires several weeks to become established (19). Side effects of 
gabapentinoids include: dizziness, peripheral oedema, dry mouth and somnolence (19). Table 
2 summarises the most commonly used analgesics in treating pain in pancreatic cancer. 
Treatment of pancreatic cancer pain often requires use of combinations of analgesics and a 
regular review of their efficacy, tolerance and side effects. As the pain mechanisms are not yet 
fully understood and several mechanisms can promote pain, use of pharmacotherapy is 
currently empirical instead of mechanism-based. TCAs, gabapentinoids, and NMDA receptor 
antagonists (ketamine and methadone) inhibit pathways known to contribute to pain in 
pancreatic cancer although, those that opioids influence are uncertain. More research is 
required to understand the relevant pathways, where opioid receptors are expressed and the 
interactions between these neurotransmitters. An appreciation of the pain mechanisms will 




Endoscopic Ultrasound Guided Celiac Plexus Neurolysis (EUS-CPN) 
 
Relevant anatomy and technique 
When analgesics do not give adequate pain relief, endoscopic techniques can be employed. 
Celiac plexus neurolysis (CPN) is the irreversible chemical ablation of this structure which 
consequently interrupts the nociceptive impulses originating in the pancreas. CPN can 
promote pain relief in patients with either pancreatic cancer or chronic pancreatitis (20) (21). 
An appreciation of the relevant neuroanatomy is important when considering application of 
this technique. Preganglionic sympathetic interconnecting fibres of the greater and lesser 
splachnic nerves, originating from the upper abdominal viscera, namely: pancreas, liver, 
spleen, kidneys, adrenals and alimentary track between stomach and transverse colon and 
connect to form the upper abdominal ganglia, i.e. the celiac, superior mesenteric and 
aorticorenal ganglia (23). The celiac ganglia are located in the retroperitoneal space, laterally 
and inferiorly to the root of the celiac artery at the T12-L2 level (22). Inferior to the celiac artery 
is the superior mesenteric ganglion, above the superior border of the superior mesenteric 
artery. The complex of the celiac, the superior and aorticorenal mesenteric ganglia form the 
celiac plexus. The number of ganglia in the plexus varies between two to five (23). The efferent 
nerve fibres that exit the celiac ganglia, constitute the greater and lesser splachnic nerves 
which then synapse at the dorsal route ganglia and enter the spinal cord. Nerve fibres from 
other intra-abdominal organs connect to the celiac plexus namely: the oesophagus, stomach, 
liver, biliary ducts, adrenal glands, small and large intestines and abdominal blood vessels. 
Different techniques to approach and destroy the celiac ganglia have evolved historically 
namely: surgical, fluoroscopic-guided, computerised tomography (CT)- guided, ultrasound- 
guided and more recently endoscopic ultrasound guided (EUS) methods. The latter is now the 
preferred technique as it allows direct visualisation of the celiac ganglia in 70-80% of patients 
(23).  At EUS, an ultrasound probe, incorporated into the tip of the gastroscope, is placed 
against the lesser curvature of the stomach enabling the sonographer to visualise the 
abdominal aorta and the root of the celiac artery (21). This allows, injection of local anaesthetic 
followed by neurolytic, dehydrated alcohol into both sides of the celiac trunk (bilateral 
injection technique) (21). Alternatively a single injection can be administered at the base of the 
celiac trunk (central injection technique). The potential benefit of bilateral injection is the wider 
spread of the neurolytic agent and therefore greater pain relief. However, this is technically 
more difficult as it requires double puncture and deeper needle insertion (24). Recently, a new 
practice has emerged where if the celiac ganglia are directly visualised the needle is advanced 
further and injection is given directly into the ganglia instead of around, a technique called 
Ganglia Plexus Neurolysis (21). Another variation of the EUS-guided technique described by a 
Japanese group is injection at the level of the superior mesenteric artery root. This later 
technique achieves better distribution of the injectate and is called Endoscopic Ultrasound 
Guided Broad Plexus Neurolysis (EUS-guided BPN) (25).  
 
Efficacy of EUS-CPN 
The efficacy of EUS-CPN in inducing analgesia, over conventional drug therapy has been 
reported in one clinical trial (28) and three meta-analysis of case series (29), (22), (30). Early 
administration of EUS-CPN at diagnosis versus conventional drug therapy was investigated in 
a randomised controlled trial of 98 patients with histologically proven, locally advanced 
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pancreatic adenocarcinoma, with pain assessed at 1 and 3 months post-procedure. The 
primary outcomes were differences between trial arms in the mean percentage and mean 
absolute changes in the 7-point Likert pain score. The secondary outcomes were: the 
differences in the mean percentage and mean absolute change in morphine equivalent units 
(MEQ) consumption, mean percentage change in DDQ-15 score (Digestive Disease Quality of 
life instrument) and survival (28). The baseline demographic and clinical characteristics at 
diagnosis were comparable between the two groups and the mean daily morphine 
consumptions in morphine equivalent units were 36.8 and 41.9 for the pharmacotherapy and 
the intervention group, respectively. The differences between the mean percentage changes 
in Likert-pain score between the two groups at 1 month was -28.9 % (95%CI, -67 to 2.8) 
(p=0.09) and at 3 months -60.7 % (95% CI, -86.6 to -25.5) (P=0.01) in favour of the EUS-CPN 
group (28). The mean morphine consumption increased in both groups by the first month 
[mean absolute change in morphine consumption +54 MEQ (CI 95% +20 to +96) in 
pharmacotherapy group vs +53 MEQ (CI 95%, +28 to +89) in the EUS-CPN group (P=0.99)]. This 
plateaued for the EUS-CPN patients at 3 months [+50 MEQ (CI 95%, +28 to +79)], but continued 
to increase in the pharmacotherapy group [+100 MEQ (CI 95%, +49 to +180) (P=0.10)] (28). 
Quality of life scores improved in both arms but there was no statistically significant difference 
between them and the mean survival was similar in both groups (data not provided) (28). To 
date, this is the only clinical trial, of which we are aware, to compare EUS-CPN against 
pharmacotherapy and has provided evidence of superiority of EUS-CPN in terms of providing 
pain relief and some evidence of lower use of morphine. However, there are several limitations 
to this study: the trial excluded 484 out of 580 patients (83.4%) at diagnosis including those 
with metastatic disease, patients with estimated survival less than 3 months some of whom 
may potentially benefit from EUS-CPN. Therefore, the generalizability of the results in patients 
with pancreatic cancer was limited.  
The complications of EUS-CPN, which are usually minor, were reported in the one clinical trial 
and several case series namely: diarrhoea, postural hypotension, alcohol inebriation and 
temporary exacerbation of pain. Diarrhoea is usually transient, lasts between 2 days to a week 
and responds well to loperamide. Typically, postural hypotension develops immediately after 
the procedure in the endoscopy recovery area when patients start mobilising and rapidly 
responds to intravenous fluids. Both diarrhoea and postural hypotension occur as the result of 
the unopposed parasympathetic activity after destruction of the sympathetic fibres in the 
coeliac ganglia. Spinal stroke distal to the T10 neurotome with permanent paraplegia is a 
severe complication of EUS-CPN, although this is exceptionally rare and has only been 
described in two case reports of one patient each (26), (27).  In the current bibliography no 
lethal complications of EUS-CPN were reported and therefore the data suggests that EUS-CPN 
is safe. 
Three meta-analyses of case series provided some evidence of the efficacy of EUS-CPN (29) 
(22) (30). The most recent and robust included 6 case series of 295 patients in total and 
reported a 4-5 points decrease in the pain visual analogue score (1-10 scale) at 1,2,4, 8 and 12 
weeks after EUS-CPN (p< 0.001 for all the follow up times) (30). The other two meta-analyses 
reported similar results: Puli et al (N=283) reported pain relief in 80% (95% CI, 74.4- 85.2) and 
Kauffman et al reviewed 3 studies (2 of which were abstracts) (N=119), with pain relief in 72.5% 
(no CI or p-values displayed)]. The results of the largest clinical studies assessing EUS-CPN 
efficacy are summarised in table 3. Currently, there are no clinical trials assessing EUS-CPN in 
patients who develop pain later after diagnosis. Clinical trials of EUS-CPN are required in 
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broader patient groups to confirm if morphine requirements are less, and importantly to 
investigate if the administration of EUS-CPN at different time intervals post-diagnosis can 
improve the efficacy of the technique as pain can develop later in the natural history of the 
cancer. Such trials should also involve patients who may not have pain at diagnosis and those 
with metastatic disease. 
 
Predictive factors for response to EUS-CPN 
Between 20-28% of patients have a limited analgesic response to EUS-CPN (30), (29), (22). 
Several observational studies have assessed predictive factors for response or suggested 
variations of the procedure to achieve a higher efficacy (31), (32), (25), (24). Direct infiltration 
of the celiac plexus by the cancer as shown on CT and restricted spread of the injectate 
predicted a negative or limited response to the procedure. In an observational study, 47 
patients with inoperable pancreatic cancer and a pain visual analogue score (VAS) ≥ 5 (0-10 
scale) received EUS-CPN. Most had no benefit from opioid analgesics, although a small 
proportion had EUS-CPN without preceding narcotic use (number not stated) (31). The 
injectate contained radiological contrast and computerised tomography (CT) immediately after 
EUS-CPN illustrated the distribution of the injectate (31). Patients’ VAS score was re-assessed 
7 days post-EUS-CPN and patients were classified into either ‘complete responders’ (VAS= 0 or 
1 or decrease by 3 points without increase in analgesics) or ‘insufficient responders’ (VAS score 
decreased < 3 points). The insufficient responders were firstly more likely to have direct celiac 
plexus infiltration from the cancer compared to the ‘complete responders’ (73.3% vs 28.1%, 
p= 0.005, odd ratio: 4.82, 95% CI=1.12-23.42) and secondly more likely to have a restricted 
injectate distribution, unilaterally to the celiac trunk (46.7% Vs 6.3%, p=0.0025, odd ratio=8.67, 
95%CI= 1.51-71.48). Whether the clinical characteristics of pain in patients with direct plexus 
cancer infiltration differ from those without is unknown and also why this leads to poor pain 
outcomes after the procedure. One possibility could be that the malignant tissue prevents the 
injectate from spreading around the ganglia or the nociceptive signals are more potent and 
frequent, so that the standard neurolysis regime is insufficient. There were no associations 
between response and: ascites, metastasis and anatomical location of the tumour within the 
pancreas (31).  
Direct visualisation of the celiac plexus at EUS is a positive predictive factor for a decrease in 
pain scores (32). In an observational study of 64 patients, 53 had EUS-CPN at the same time as 
the diagnostic EUS for suspected pancreatic cancer and were investigated for associations with 
8 variables namely: direct visualisation of the celiac ganglia, VAS score at baseline ≥7, gender, 
age ≥ 65 years, tumour size≥ 25 mm, tumour anatomical location, histologically confirmed 
diagnosis and EUS-CPN at the same time as diagnostic EUS. Patients with direct ganglia 
visualisation were more likely to improve (decrease in pain score by 2 points on a 0-10 scale 
pain visual analogue score) (odd ratio: 15, p<0.001) (32).  This indicates that a successful pain 
outcome is possibly linked with injection of the neurolytic agent as proximally as possible to 
the targeted ganglion. The other variables were not associated with response. Therefore, a 
successful response to EUS-CPN is more likely to occur in patients without tumour involvement 
of the coeliac plexus, where the neurolytic agent has a broader distribution and where the 




Chemotherapy improves pain in pancreatic cancer 
 
Chemotherapy in pancreatic cancer is prescribed to patients to improve survival but also has 
analgesic properties. In total, 16 clinical trials, published since 1997, investigated the efficacy 
of chemotherapeutics for inoperable pancreatic cancer and also reported changes in pain 
scores, either as an individual outcome or as one of the components of a quality of life 
assessment (33). These trials assessed pain either as a continuous score (0-100 or 0-10 scales) 
or as a proportion of participants who had ≥50% reduction in pain intensity or opioid 
consumption.  The chemotherapies assessed were: gemcitabine, 5-fluorouracil, FOLFIRINOX, 
BAY12-9566 metalloproteinase, glufosphamide and combinations of gemcitabine with 
cicplatin, merimastat, permetexed, exatecan,capecitabine, axitinibe, bevacizumab, cetuximab, 
paclitaxel and combinations of 5-fluorouracil with mitomycin. Pain improved with every 
treatment regime apart from the BAY12-9566 and the best supportive care (33). Patients who 
received gemcitabine, the most widely used chemotherapeutic in pancreatic cancer, were 
more likely to report a reduction in pain compared to other monotherapies, whilst 
combinations of gemcitabine with other chemotherapeutics achieved better pain 
improvements compared to gemcitabine monotherapy (33). The reduction in pain scores 
varied from 8 to 25 points on a 0-100 scale (8 point reduction reported in patients who received 
gemcitabine either as monotherapy or as combination with capecitabine, and 25 in patients 
treated with FOLFIRINOX).The proportion of patients who reported ≥50% reduction in pain 




Abdominal pain in pancreatic cancer is a common debilitating symptom which impacts 
negatively on patients’ quality of life and leads to increased health care needs and costs, 
including frequent medical consultations, palliative and nursing care. Pain contributes to a 
decline in patients’ performance status and therefore can adversely influence their eligibility 
for chemotherapy. Pain is frequently refractory even to strong opioid analgesics, whose side 
effects can further precipitate a decline in clinical status. Patients with pancreatic cancer pain 
have reduced survival times compared to those without and better analgesia may improve 
survival. Pain can be due to pancreatic ductal obstruction and/or pancreatic neuropathy. 
Standard practice for promoting analgesia is pharmacological therapy according to the WHO 
analgesic ladder. If pain is resistant to opioid therapy ketamine or EUS-CPN is indicated.  The 
literature has reported pain improvement and reduction in morphine use in patients treated 
with EUS-CPN, although further clinical trials are required to refine its use, including the timing 
of administration and the precise technique. An in depth understanding of the pain 
mechanisms will enable individualised care, with particular analgesics antagonising the 
relevant pain pathways and inhibiting the neuropathic changes. Such developments will 
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